European Commission green lights Servier’s Tibsovo by John Pinching | May 11, 2023 | News | 0 Treatment concerns patients with IDH1-mutated acute myeloid leukaemia and IDH1-mutated cholangiocarcinoma Read More
US approves first-in-class targeted AML therapy by Selina McKee | Jul 23, 2018 | News | 0 US regulators have approved the first targeted therapy for patients with relapsed or refractory acute myeloid leukemia carrying a certain genetic mutation. Read More